Comparison of the protective effect of formoterol and of salmeterol against exercise-induced bronchospasm when given immediately before a cycloergometric test

Respiration

Volumn 69, Issue 6, 2002, Pages 509-512

  Ferrari, Marcello ^a,b   Segattini, Carlo ^a   Zanon, Roberto ^a   Bertaiola, Mariano ^a   Balestreri, Filippo ^a   Brotto, Emanuele ^a   Lo Cascio, Vincenzo ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b Policlinico GB Rossi   (Italy)

Author keywords

Exercise induced bronchospasm; Formoterol; Long acting 2 agonist; Salmeterol

Indexed keywords

FORMOTEROL; SALMETEROL;

ADOLESCENT; ADULT; ARTICLE; ASTHMA; BRONCHOSPASM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; EXERCISE; EXERCISE TEST; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MALE; METERED DOSE INHALER; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; ASTHMA, EXERCISE-INDUCED; CHILD; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ETHANOLAMINES; EXERCISE TEST; FEMALE; HUMANS; MALE; TREATMENT OUTCOME;

EID: 0036442867     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000066458     Document Type: Article

References (12)

1. Anderson SD, Seale JP, Ferris L, Schoeffel RE, Lindsay DA: An evaluation of pharmacotherapy for exercise-induced asthma. J Allergy Clin Immunol 1979;64:612-624.
2. Konig P, Hardnik BS, Serely CV: Fenoterol in exercise-induced asthma. Effect of dose on efficacy and duration of action. Chest 1984;85: 462-464.
3. Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, Lötwall J: Inhaled dry-powder formoterol and salmeterol in asthmatic patients: Onset of action, duration of effect and potency. Eur Respir J 1997;10:2484-2489.
4. Van Noord JA, Smeets JJ, Raaijmakers JAM, Bommer AM, Maesen FPV: Salmeterol versus formoterol in patients with moderately severe asthma: Onset and duration of action. Eur Respir J 1996;9:1684-1688.
5. Politiek MJ, Boorsma M, Aalbers R: Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction. Eur Respir J 1999;13:988-992.
6. Wagener T, Hedenström H, Melander B: Rapid onset of action of inhaled formoterol in asthmatic patients. Chest 1992;102:535-538.
7. Patessio A, Podda A, Carone M, Trombetta N, Donner CF: Protective effect and duration of action of formoterol aerosol on exercise-induced asthma. Eur Respir J 1991;4:296-300.
8. Kemp JP, Dockhorn RJ, Busse WW, Bleeker ER, Van As A: Prolonged effect of inhaled salmeterol against exercise-induced bronchospasm. Am J Respir Crit Care Med 1994;150: 1612-1615.
9. Anderson SD, Rodwell LT, Du Toit J, Young IH: Duration of protection by inhaled salmeterol in exercise-induced asthma. Chest 1991; 100:1254-1260.
10. American Thoracic Society: Guidelines for the diagnosis and care of patients with chronic pulmonary diseases (COPD) and asthma. Am Rev Respir Dis 1987;136:225-244.
11. Ferrari M, Balestreri M, Baratieri S, Biasin C, Oldani V, Lo Cascio V: Evidence of the rapid protective effect of formoterol dry-powder inhalation against exercise-induced bronchospasm in athletes with asthma. Respiration 2000;67:510-513.
12. Jones NL, Makrides L, Hitchoch C, Chypchar T, McCartney N: Normal standards for incremental progressive cycle ergometer test. Am Rev Respir Dis 1985;131:700-708.